What question did this study set out to answer?

This meta-analysis aims to compare response rates of different Bruton tyrosine kinase inhibitors in treating B cell lymphomas.

March 10, 2026Open Access

A Meta-analysis Investigating Response Rates with Continuous Bruton Tyrosine Kinase Inhibitor Monotherapies in the Treatment of B Cell Lymphomas

Puntos clave

This meta-analysis aims to compare response rates of different Bruton tyrosine kinase inhibitors in treating B cell lymphomas.
Compilation of existing head-to-head trial data
Comparison of complete response (CR) and overall response rates (ORR) among treatments
Assessment of outcomes specific to each B cell lymphoma indication
Zanubrutinib shows statistically significant improvement in CR compared to acalabrutinib and ibrutinib
Overall response rates of zanubrutinib are numerically higher across various B cell lymphomas
Trends indicate consistent effectiveness of zanubrutinib within different lymphoma types

Resumen

Consistent with the results of existing head-to-head trials, zanubrutinib demonstrated either numerically or statistically significant improved CR and ORR compared to acalabrutinib and ibrutinib across B cell lymphomas. Similar trends were observed within each indication. These findings suggest that zanubrutinib is the most effective BTKi treatment option for patients across B cell lymphomas.

Me gusta

Guardar

Ver artículo completo